Greg has made over 18 trades of the AMAG Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently Greg sold 15,318 units of AMAG stock worth $73,680 on 15 February 2018.
The largest trade Greg's ever made was selling 18,248 units of AMAG Pharmaceuticals stock on 30 January 2017 worth over $84,853. On average, Greg trades about 2,694 units every 30 days since 2013. As of 15 February 2018 Greg still owns at least 414,086 units of AMAG Pharmaceuticals stock.
You can see the complete history of Greg Madison stock trades at the bottom of the page.
Greg's mailing address filed with the SEC is 100 HAYDEN AVENUE, , LEXINGTON, MA, 02421.
Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C...., and Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
AMAG Pharmaceuticals executives and other stock owners filed with the SEC include: